Abstract. Protein kinase C (PKC) activity is elevated in malignant compared with that in normal human breast tissue. In the present study, we investigated the regulatory mechanism and the co-relationship between PKC-α and estrogen receptor-α (ER-α) in ER-α-positive and tamoxifen-resistant (TAMR) breast cancer cells. Our results showed that the level of ER-α expression was significantly decreased in TAMR when compared with that in tamoxifen-sensitive (TAMS) breast cancer cells. However, PKC-α phosphorylation was increased in TAMR breast cancer cells when compared to that in TAMS breast cancer cells. Additionally, ER-α expression was significantly decreased due to the overexpression of constitutively active PKC-α (CA-PKC-α). Next, we investigated the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA), a reversible activator of PKC, on ER-α expression in ER-α-positive breast cancer cells. TPA decreased the levels of ER-α expression in a time-and dose-dependent manner. In contrast, the TPA-induced downregulation of ER-α was prevented by Go6983, a specific PKC inhibitor. Notably, we found that CA-PKC-α suppressed c-JUN phosphorylation, which is a major activating protein-1 factor, and TPA-induced downregulation of ER-α was prevented by SR11302, a specific activator protein-1 inhibitor. Taken together, we demonstrated that PKC-α activity suppressed the level of ER-α expression by inhibiting c-JUN phosphorylation in ER-α-positive breast cancer cells. Therefore, we suggest that PKC-α may be a potential therapeutic target for treating ER-positive and TAMR breast cancer.
Introduction
The estrogen receptors (ERs) ER-α and ER-β are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors (1) . The status of ER expression in human breast tumors is an extremely important prognostic marker for selecting the appropriate hormonal therapy (2, 3) . Approximately 75% of breast cancers express ER and/or the progesterone receptor (PR) and are treated with targeted antiestrogen therapy such as tamoxifen (2, 4) .
Tamoxifen is widely used for treating hormone-dependent, ER/PR-positive breast cancer (5) . It is effective for inducing the arrest of tumor progression in 50% of patients with breast cancer (6) . However, although anti-estrogen therapies targeting ER-α prevent disease recurrence in patients with hormonedependent breast cancer, de novo or acquired resistance remains a major problem (7, 8) . To date, many mechanisms have been suggested for the tamoxifen-resistant model, yet the mechanisms are not fully understood.
Protein kinase C (PKC) is a member of a family of serine/threonine protein kinases and is involved in a wide variety of fundamental physiological processes including cell proliferation and apoptosis (9, 10) . Estrogen-treated breast cancer cells such as MCF-7 and HCC38 show rapid increases in PKC activity (11) . PKC activity is significantly elevated in malignant tumor tissues when compared with that in normal human breast tissues (12) . We reported that PKC-α mediates cell invasion and migration by inducing matrix metalloproteinase (MMP)-1 and MMP-9 expression in breast cancer cells (13) .
The aim of the present study was to investigate the effect of PKC-α on the level of ER-α expression and the regulatory mechanism of PKC-α-induced downregulation of ER-α in ER-positive breast cancer cells.
Materials and methods
Reagents. 4-Hydroxytamoxifen (4-OHT) was purchased from Sigma (St. Louis, MO, USA). Fetal bovine serum (FBS), RPMI-1640 and Dulbecco's modified Eagle's medium (DMEM) were purchased from Thermo Scientific (Hemel Hempstead, UK). Penicillin (100 U/ml) and 100 mg/ml streptomycin were purchased from Life Technologies (Rockville, MD, USA). Go6983 was purchased from Tocris (Ellisville, MO, USA). SR11304 and mouse monoclonal anti-ER-α and anti-β-actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 12-O-Tetradecanoylphorbol-13-acetate (TPA) was purchased from R&D Systems (Minneapolis, MN, USA). The ECLplus reagents were from Amersham (Buckinghamshire, UK).
Cell culture and establishment of tamoxifen-resistant (TAMR) MCF-7 breast cancer cells. MCF-7 breast cancer cells were grown in a humidified atmosphere of 95% air and 5% CO 2 at 37˚C in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin. T47D and ZR75-1 breast cancer cells were cultured in RPMI-1640. The TAMR breast cancer cell line was kindly provided by Professor Keun Wook Kang (Seoul National University, Seoul, Korea). The TAMR cell line was established using a previously reported methodology (14) . Briefly, MCF-7 cells were washed with PBS, and the culture medium was replaced with phenol red-free DMEM containing 10% charcoalstripped steroid-depleted FBS (HyClone, Logan, UT, USA) and 0.1 mM 4-OHT. The cells were continuously exposed to this treatment regimen for 2 weeks, and the 4-OHT concentration was increased gradually up to 3 mM over a 9-month period. Initially, cell growth rates were depressed. However, after exposure to the medium for 9 months, the rate of cell growth increased gradually, indicating the establishment of tamoxifen-resistant cells.
Cell proliferation. Cell proliferation was measured using a Countess ® automated cell counter (Invitrogen, Carlsbad, CA, USA). Cells were plated at 5x10 4 /well in 6-well plates. Tamoxifen-sensitive (TAMS) and TAMR cells were incubated in phenol red-free DMEM containing 10% charcoal-stripped steroid-depleted FBS with or without 3 mM 4-OHT for the indicated times.
Western blotting. The cell lysates were used in the immunoblot analysis for ER-α, PKC-α and β-actin. The proteins were boiled for 5 min in Laemmli sample buffer and then electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. The proteins were transferred to PVDF membranes, and the membranes were blocked with 10% skim milk in TBS with 0.01% Tween-20 for 15 min. The blots were incubated with anti-matrix metalloproteinase (MMP)-1, PKC-α and β-actin antibodies (1:1,000 dilution) in 1% TBS/T buffer (0.01% Tween-20 in TBS) at 4˚C overnight. The blots were washed three times, in TBS with 0.01% Tween-20, and they were subsequently incubated with antirabbit peroxidase-conjugated antibody (1:2,000 dilution) in TBS/T buffer. After a 1-h incubation at room temperature, the blots were washed three times and enhanced chemiluminescence reagents (Amersham Bioscience) were used for development.
Real-time polymerase chain reaction (RT-PCR).
Total RNA was extracted from the cells using TRIzol reagent (Invitrogen), according to the manufacturer's protocol. Isolated RNA samples were then used for RT-PCR. Samples (1 µg total RNA) were reverse-transcribed into cDNA in 20-µl reaction volumes using a First-Strand cDNA Synthesis kit for RT-PCR, according to the manufacturer's instructions (MBI Fermentas, Hanover, MD, USA).
Gene expression was quantified by real-time PCR using a SensiMix SYBR kit (Bioline Ltd., London, UK) and 100 ng of cDNA per reaction. The sequences of the primer sets used for this analysis were: human ER-α (forward, 5'-CGC TAC TGT GCA GTG TGC AAT-3' and reverse, 5'-CCT CAC AGG ACC AGA CTC CAT AA-3') and GAPDH as an internal control (forward, 5'-ATT GTT GCC ATC AAT GAC CC-3' and reverse, 5'-AGT AGA GGC AGG GAT GAT GT-3'). An annealing temperature of 60˚C was used for all primers. PCRs were performed in a standard plate format with an ABI 7900HT real-time PCR detection system. The raw threshold cycle (C T ) value was first normalized to the housekeeping gene for each sample to obtain ΔC T . The normalized ΔC T was then calibrated to the control cell samples to obtain ΔΔC T . All cDNA samples were analyzed in three independent experiments.
PKC-α siRNA and myr-PKC-α transfection. PKC-α siRNA was purchased from Bioneer Corp. (Daejeon, Korea). Myr-PKC-α FLAG was a gift from Dr R.R. Hodges (Addgene plasmid #10807) (15) . We found that the optimal siRNA knockdown and overexpression conditions involved transfection of the MCF-7 breast cancer cells at 80% confluence, and the cells were maintained in DMEM with 10% FBS; Effectene ® (Qiagen, Valencia, CA, USA) was used for the transfections with PKC-α siRNA (25 and 50 nM, or as noted) or Myr-PKC-α FLAG following the manufacturer's protocols. Fresh serum-free media with or without 20 nM TPA were added 24 h after the 48-h transfection. The level of PKC-α protein expression was analyzed by western blotting.
Statistical analysis. Statistical significance was determined using the Student's t-test. Results are presented as means ± standard errors. All P-values are two-tailed, and differences were considered significant at P<0.05.
Results

Inverse co-relationship between PKC-α and ER-α in the TAMR cell line.
We chose TAMS and TAMR MCF-7 breast cancer cells to verify the relationship between PKC-α and ER-α. We treated each cell type with 3 mM 4-OHT for the indicated times. As shown in Fig. 1A , the proliferation of TAMS cells in response to 3 mM 4-OHT was significantly suppressed. However, the proliferation of 3 mM 4-OHT-treated TAMR cells increased in a time-dependent manner, and the gap in proliferation was significantly different after 6 days (Fig. 1A) . We also compared the expression level of PKC-α and ER-α in TAMS and TAMR cells. The levels of ER-α protein and mRNA expression were significantly decreased in the TAMR cells when compared with the levels in TAMS cells (Fig. 1B  and C) . In contrast, PKC-α phosphorylation was significantly increased in the TAMR cells (Fig. 1B) . Therefore, an inverse correlation was noted between PKC-α and ER-α in the TAMR MCF-7 breast cancer cell line. Fig. 1 , we examined the direct relationship between PKC-α and ER-α in ER-positive breast cancer cells. The cells were transfected with CA-PKC-α for 48 h, and the cell lysates were harvested to detect PKC-α and ER-α expression. The results showed that the level of ER-α expression decreased due to CA-PKC-α overexpression in MCF-7 and ZR75-1 breast cancer cells ( Fig. 2A and B) . Therefore, we demonstrated that the level of ER-α expression was regulated through a PKC-α-dependent mechanism in ER-positive breast cancer cells.
Overexpression of constitutively active PKC-α (CA-PKC-α) decreases the level of ER-α expression in ER-α-positive breast cancer cells. Based on
Expression of ER-α was decreased in ER-α-positive breast cancer cells by TPA in a time-and dose-dependent manner.
Next, we investigated the effect of TPA on ER-α expression. TPA is a natural molecule that is a well-known tumor promoter and reversible activator of PKC (16) . We treated MCF-7 cells with 10 nM TPA for the indicated times. As shown in Fig. 3A , the level of ER-α protein expression was decreased in a timedependent manner following TPA treatment. Furthermore, ER-α protein expression in response to TPA was significantly decreased in T47D and ZR75-1 breast cancer cells (Fig. 3B) . In addition, we confirmed the level of ER-α mRNA expression following TPA treatment. The level of ER-α mRNA expression was also significantly decreased to 0.2±0.06-fold (in MCF-7 cells), 0.34±0.04-fold (in T47D cells) and 0.39±0.23-fold (in ZR75-1 cells) of the control level following 10 nM TPA treatment, respectively (Fig. 3C) . These results demonstrated that TPA downregulates the expression of ER-α by activating PKC-α in ER-positive breast cancer cells.
TPA-induced downregulation of ER-α is mediated by a PKC-α-dependent pathway but not by a PI-3K/Akt-dependent pathway or p38-dependent pathway.
To investigate the regulatory mechanisms of TPA-induced downregulation of ER-α, we treated ER-positive breast cancer cells with specific inhibitors such as the PKC inhibitor Go6983, the PI-3K inhibitor LY294002, and the p38 inhibitor SB203580. Our results showed that TPA-induced downregulation of ER-α protein and mRNA expression was prevented by Go6983 in MCF-7 cells but not by LY294002 or SB203580 (Fig. 4A) . The level of ER-α mRNA expression was significantly decreased to 0.35±0.03-fold of the control level following TPA treatment (Fig. 4A) . In contrast, TPA-induced downregulation of ER-α mRNA expression was suppressed to 1.37±0.01-fold of the control level by 10 µM Go6983 treatment (Fig. 4A) . Under the same conditions, our results also showed that TPA-induced downregulation of ER-α protein and mRNA expression was prevented by Go6983 in T47D (Fig. 4B) and ZR75-1 (Fig. 4C ) breast cancer cells. Therefore, we demonstrated that TPA also regulates ER-α expression through a PKC-dependent pathway in ER-positive breast cancer cells. 
PKC-α regulates ER-α expression by suppressing c-Jun activity in ER-α-positive breast cancer cells.
Finally, we investigated whether the activator protein-1 (AP-1) transcriptional factor affects the level of ER-α expression in ER-positive breast cancer cells. After treatment with 3 µM SR11302 for 24 h, the cells were harvested for detection of ER-α mRNA and protein expression. Our results showed that the levels of ER-α protein and mRNA expression was significantly decreased following SR11302 treatment of ER-α-positive breast cancer cells (Fig. 5A-C) . In addition, we examined the level of c-JUN phosphorylation in CA-PKC-α-overexpressing MCF-7 cells. As shown in Fig. 5D , the level of c-JUN phosphorylation was decreased due to CA-PKC-α overexpression. Therefore, we demonstrated that PKC-α downregulated ER-α expression by suppressing AP-1 activity in ER-α-positive breast cancer cells.
Discussion
Although tamoxifen is widely used to treat all stages of breast cancer, almost 50% of patients with breast cancer fail to respond to tamoxifen and eventually acquire tamoxifen resistance, leading to tumor progression and death (8, 17) . The exact regulatory mechanism of tamoxifen resistance is not fully understood. In the present study, we investigated whether the level of ER-α expression is regulated by a PKC-α-dependent pathway in ER-α-positive breast cancer cells. PKC, a serine/threonine kinase, regulates proliferation, differentiation and apoptosis in a variety of cells including breast and ovarian cancer cells (18, 19) . We previously reported that TPA-induced MMP-1 and MMP-9 expression is mediated through a PKC-α-dependent pathway in breast cancer cells (13) . Upregulation of PKC-α and PKC-ε is correlated with stimulation of human endometrial cancer growth by tamoxifen (20) . Consistent with this report, the PKC-α phosphorylation level was significantly augmented in the TAMR cell line compared with that in the TAMS cell line. Overexpression of CA-PKC-α significantly decreased the level of ER-α mRNA and protein expression in breast cancer cells. Thus, we suggest that PKC-α expression or activity may predict tamoxifen treatment failure.
Furthermore, the tumor promoter TPA is a natural molecule and reversible activator of PKC (16) . TPA suppressed ER expression in MCF-7 cells, similar to estrogen treatment and increased ER phosphorylation (21) . Elevated PKC activity suppressed ER expression in breast cancer (22, 23) . In addition, PKC-α levels may increase in patients with breast cancer resulting in low or negative ER levels compared to those in ER-positive patients (10, 22, 23) . PKC-α overexpression is associated with a more aggressive neoplastic phenotype in MCF-7 breast cancer cells (24) . Although we used treatment with TPA to activate PKC in breast cancer cells, our results showed that ER-α mRNA and protein expression decreased. Therefore, we suggest that activation of PKC-α may trigger tamoxifen resistance by downregulating ER-α in breast cancer cells.
AP-1 is a member of the Jun and/or Fos family. The AP-1 complex regulates transcriptional activity of a variety of genes including ER-α (25) . ER-α efficiently binds to c-Jun and JunB but does not directly bind to any Fos family members (26) . The induction of AP-1 transcriptional activity requires TPA-induced tumor promotion (27) . Importantly, our results showed that CA-PKC-α overexpression significantly decreased c-Jun phosphorylation. In addition, the ER-α expression level was suppressed by SR11302, an inhibitor of AP-1. Therefore, we demonstrated that activation of PKC-α suppressed the level of ER-α expression by inhibiting AP-1 activity in TAMR and ER-positive breast cancer cells.
In conclusion, we demonstrated an inverse relationship between PKC-α activity and the level of ER-α expression in TAMR and ER-positive breast cancer cells. PKC-α suppressed the level of ER-α expression by inhibiting c-Jun phosphorylation in ER-positive breast cancer cells. Therefore, we suggest that PKC-α may be a potential therapeutic target in TAMR and ER-positive breast cancer.
